Exemplary Support for the amendment of claim 14 is in the Specification under the heading "I. Detection of **specific binding**, and screening test compounds, using reporter gene assays', (Emphasis added) pages 52-55, and in particular, the teaching:

> "Alternatively, **one control** involves using the consensus-κB sequence by detecting unaltered binding of an isolated nucleotide sequence comprising the consensus-κB sequence 5'-GGGACTTTCC-3' (**SEQ ID NO:58**) to a polypeptide comprising one or more of RelB RHD, as exemplified by **SEQ ID NO:62**, and RelB in the presence of the one or more test compounds." (Emphasis added) Specification, page 55, lines 26-30.

ACCEPTED PROPOSED EXAMINER AMENDMENT TO PLACE THE APPLICATION IN CONDITION FOR ALLOWANCE

1-6 **(Canceled)**

7. (**Currently amended**) A method for identifying one or more test compounds that alters binding of RelB Rel homology domain (RelB RHD) with RelBκB sequence, comprising:

a) providing

i) an isolated nucleotide sequence comprising 5'-NGGAGANNTG-3' (SEQ ID NO:57); wherein N at position 1 is chosen from G and A, N at position 7 is chosen from T and C, and N at position 8 is chosen from T and C, and wherein said isolated sequence specifically binds with a polypeptide sequence comprising RelB Rel homology domain (RHD) ~~listed as~~ comprising SEQ ID NO:62,

ii) a polypeptide comprising RelB RHD ~~listed as~~ comprising SEQ ID NO:62, and

iii) one or more test compounds;

b) contacting said isolated nucleotide sequence with said polypeptide ~~comprising RelB RHD listed as SEQ ID NO:62~~ in the presence and absence of said one or more test compounds; and

c) determining the level of specific binding of said nucleotide sequence with said ~~SEQ ID NO:62~~ polypeptide in the presence of said one or more test compounds compared to in the absence of said one or more test compounds, wherein detecting altered specific binding of said nucleotide sequence with said ~~SEQ ID NO:62~~ polypeptide in the presence of said one or more test compounds compared to in the absence of said one or more test compounds identifies said one or more test compounds as altering binding of RelB RHD with RelBκB sequence.

8. **(Original)** The method Claim 7, wherein said polypeptide is recombinant.

9. **(Original)** The method of Claim 8, wherein said polypeptide comprises RelB:p52.

10. **(Original)** The method of Claim 8, wherein said polypeptide comprises RelB.

11. **(Original)** The method of Claim 8, wherein said contacting is *in vivo*.

12. **(Original)** The method of Claim 8, wherein said contacting is *in vitro*.

13. **(Currently amended)** The method of Claim 7, further comprising detecting unaltered binding of said nucleotide sequence to a protein comprising one or more of (a) RelA Rel homology domain (RelA RHD) listed as SEQ ID NO:65, (b) RelA, (c) p50, (d) RelA:p50, (e) p52, and (f) RelA:p52, ~~(g) RelB RHD, (h) RelB, and (i) RelB:p50~~, in the presence and absence of said one or more test compounds, wherein said unaltered binding indicates specific binding of said nucleotide sequence with said polypeptide.

14. **(Currently amended)** The method of Claim 7, further comprising detecting unaltered binding of an isolated nucleotide sequence comprising the consensus-κB sequence 5'-GGGACTTTCC-3' (SEQ ID NO:58) to a polypeptide comprising one or more of RelB RHD ~~listed as~~ comprising SEQ ID NO:62, and RelB in the presence of said one or more test compounds, wherein said unaltered binding indicates specific binding of said nucleotide sequence with said polypeptide.

15-19. **(Canceled)**

Best regards,

Maha A. Hamdan
Registration No. 43,655

Medlen & Carroll, LLP
101 Howard Street, Suite 350
San Francisco, CA 94105
Tel: 510-559-8131 (Direct), 415-904-6500
Fax: 510-526-1656 (Direct), 415-904-6510
E-mail:mahamdan@medlencarroll.com